Actively Recruiting
Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients
Led by Insel Gruppe AG, University Hospital Bern · Updated on 2024-07-08
120
Participants Needed
1
Research Sites
251 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Clinical trial investigating the chemotherapeutic compound treosulfan (Trecondi® Ideogen) in myeloma patients.
CONDITIONS
Official Title
Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Myeloma patients after standard first-line induction treatment; additional induction allowed for refractory cases
- Fit for high-dose chemotherapy and autologous stem cell transplantation
- Age between 18 and 75 years
- ECOG performance status less than 3
- Creatinine clearance of 35 ml/min or higher
- Left ventricular ejection fraction 40% or higher within 3 months before study treatment
- Voluntary written informed consent given
You will not qualify if you...
- Uncontrolled acute infection
- Transplantation comorbidity index (HCTCI) greater than 6 points
- Active malignant disease except certain early-stage skin or cervical cancers or early prostate cancer; other cancers must be treated and inactive for at least 6 months
- Major bleeding disorders or coagulopathy
- Medical conditions interfering with treatment completion or tolerance
- Lack of cooperation for study treatment
- Known pregnancy or breastfeeding; inadequate contraceptive measures during and 12 months after treatment
- Use of investigational anti-cancer agents within 14 days before trial start
- Known allergies or contraindications to chemotherapy drugs used in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Departement of Medical Oncology, University Hospital Berne
Bern, Switzerland, 3010
Actively Recruiting
Research Team
T
Thomas Pabst, Prof Dr. med
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here